These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15516004)

  • 1. Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients.
    Trakarnvanich T; Thitiarcharkul S
    J Med Assoc Thai; 2004 Sep; 87(9):1041-7. PubMed ID: 15516004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM; Collins DM; Penner SB
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin response and route of administration.
    Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route.
    Navarro JF; Teruel JL; Marcén R; Ortuño J
    Scand J Urol Nephrol; 1995 Mar; 29(1):11-4. PubMed ID: 7618043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial.
    Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of single-needle versus double-needle hemodialysis in chronic renal failure.
    Trakarnvanich T; Chirananthavat T; Ariyakulnimit S; Maneerat P; Chabsuwan S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S196-206. PubMed ID: 17044473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).
    Flaharty KK
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):9S-14S. PubMed ID: 2345710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
    Janicka L; Ksiazek A; Baranowicz I; Mierzicki P
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.